{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T02:41:14Z","timestamp":1774665674162,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1157\/13107365","type":"journal-article","created":{"date-parts":[[2007,8,13]],"date-time":"2007-08-13T15:07:09Z","timestamp":1187017629000},"page":"104-115","source":"Crossref","is-referenced-by-count":11,"title":["Mieloma m\u00faltiple"],"prefix":"10.1016","volume":"129","author":[{"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Victoria Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Fernando","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13107365_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1157\/13107365_bib2","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.ejca.2005.11.035","article-title":"Myeloma bone disease and treatment options","volume":"42","author":"Yeh","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1157\/13107365_bib3","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13107365_bib4","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur J Cancer"},{"issue":"Supl 1","key":"10.1157\/13107365_bib5","first-page":"48","article-title":"Gu\u00eda para el uso de agentes eritropoy\u00e9ticos en tratamien to de soporte de hemopat\u00edas malignas [resumen]","volume":"88","author":"Garc\u00eda-Sanz","year":"2003","journal-title":"Haematologica"},{"key":"10.1157\/13107365_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.beha.2005.01.013","article-title":"Renal, hematologic and infectious complications in multiple myeloma","volume":"18","author":"Blade","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1157\/13107365_bib7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11864-003-0026-7","article-title":"Myeloma: update on supportive care strategies","volume":"4","author":"San Miguel","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"10.1157\/13107365_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1055\/s-2003-44554","article-title":"Hyperviscosity syndrome in plasma cell dyscrasias","volume":"29","author":"Mehta","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1157\/13107365_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","article-title":"Guidelines on the diagnosis and managementof multiple myeloma 2005","volume":"132","author":"Smith","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1157\/13107365_bib10","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2006-03-008953","article-title":"Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials","volume":"108","author":"Drayson","year":"2006","journal-title":"Blood"},{"key":"10.1157\/13107365_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jim.2003.09.018","article-title":"An ultrasensitive method forthe detection of oligoclonal IgG bands","volume":"284","author":"Sadaba","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1157\/13107365_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem"},{"key":"10.1157\/13107365_bib13","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13107365_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(03)12457-9","article-title":"Serum test for assessment of patients with Bence Jones myeloma","volume":"361","author":"Bradwell","year":"2003","journal-title":"Lancet"},{"key":"10.1157\/13107365_bib15","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood.V97.9.2900","article-title":"Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma","volume":"97","author":"Drayson","year":"2001","journal-title":"Blood"},{"key":"10.1157\/13107365_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.beha.2005.01.008","article-title":"Multiple myeloma: clinical features and indications for therapy","volume":"18","author":"Dispenzieri","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1157\/13107365_bib17","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garc\u00eda-Sanz","year":"1999","journal-title":"Blood"},{"key":"10.1157\/13107365_bib18","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1157\/13107365_bib19","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-04-1489","article-title":"Genetic abnormalities and patterns of antigenic expression in multiple myeloma","volume":"11","author":"Mateo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1157\/13107365_bib20","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"San Miguel","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13107365_bib21","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ejca.2005.11.039","article-title":"Conventional diagnostics in multiple myeloma","volume":"42","author":"San Miguel","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1157\/13107365_bib22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ijc.20491","article-title":"Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients","volume":"112","author":"Garc\u00eda-Sanz","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1157\/13107365_bib23","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.V91.9.3366","article-title":"Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes","volume":"91","author":"P\u00e9rez-Sim\u00f3n","year":"1998","journal-title":"Blood"},{"key":"10.1157\/13107365_bib24","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2004-04-1319","article-title":"Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma","volume":"104","author":"Guti\u00e9rrez","year":"2004","journal-title":"Blood"},{"key":"10.1157\/13107365_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13107365_bib26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1157\/13107365_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolvingtype","volume":"123","author":"Rosinol","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1157\/13107365_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11864-002-0015-2","article-title":"Solitary bone plasmacytoma and extramedullary plasmacytoma","volume":"3","author":"Dimopoulos","year":"2002","journal-title":"Curr Treat Options Oncol"},{"key":"10.1157\/13107365_bib29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/asheducation-2005.1.360","article-title":"POEMS syndrome","author":"Dispenzieri","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1157\/13107365_bib30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.beha.2005.01.012","article-title":"Prognostic features of multiple myeloma","volume":"18","author":"San Miguel","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1157\/13107365_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1157\/13107365_bib32","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in multiple myeloma patients","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1157\/13107365_bib33","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13107365_bib34","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"},{"key":"10.1157\/13107365_bib35","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification versus continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13107365_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13107365_bib37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1157\/13107365_bib38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1470-2045(06)70657-X","article-title":"Advances in oral therapy for multiple myeloma","volume":"7","author":"Morgan","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1157\/13107365_bib39","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13107365_bib40","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1157\/13107365_bib41","first-page":"205","article-title":"Novel drugs for multiple myelo ma [resumen]","volume":"11","author":"San Miguel","year":"2006","journal-title":"Education Program of the 11+ Congress of the European Hematology Association"},{"key":"10.1157\/13107365_bib42","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1157\/13107365_bib43","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexametha sone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1157\/13107365_bib44","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"10.1157\/13107365_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1517\/14656566.7.2.195","article-title":"Thalidomide in multiple myeloma","volume":"7","author":"Garc\u00eda-Sanz","year":"2006","journal-title":"Expert Opin Pharma-cother"},{"key":"10.1157\/13107365_bib46","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13107365_bib47","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1157\/13107365_bib48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1157\/13107365_bib49","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13107365_bib50","first-page":"621","article-title":"Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study","volume":"91","author":"De la Rubia","year":"2006","journal-title":"Haematologica"},{"key":"10.1157\/13107365_bib51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2141.2003.04237.x","article-title":"Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation","volume":"121","author":"P\u00e9rez-Sim\u00f3n","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1157\/13107365_bib52","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","year":"2001","journal-title":"BrJ Haematol"},{"key":"10.1157\/13107365_bib53","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2006-03-013086","article-title":"Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma","volume":"108","author":"Offidani","year":"2006","journal-title":"Blood"},{"key":"10.1157\/13107365_bib54","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1157\/13107365_bib55","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1157\/13107365_bib56","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13107365_bib57","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"key":"10.1157\/13107365_bib58","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775307727690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775307727690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T20:44:00Z","timestamp":1587847440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775307727690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0025775307727690"],"URL":"https:\/\/doi.org\/10.1157\/13107365","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}